This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas and Drais, through new virtual firm Tacurion, develop ASP7035
08 May 2013
Once again, Astellas Pharma Inc. and Drais Pharmaceuticals Inc. (clinical-stage drug development) have signed an agreement for the development and commercialization of an Astellas compound, this time the Phase IIa-ready vasopressin V2 receptor selective agonist ASP7035 for nocturia (waking up at night to urinate). Astellas will transfer ownership of the compound to Tacurion Pharma Inc., a virtual company to be operated by Drais’ executive team.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?